Alnylam Pharmaceuticals, Inc. (ALNY)

$165.7

+8.3

(+5.27%)

Market is closed - opens 7 PM, 24 Jun 2024

Insights on Alnylam Pharmaceuticals, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 439.71M → 494.33M (in $), with an average increase of 11.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -137.87M → -65.93M (in $), with an average increase of 109.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 77.4% return, outperforming this stock by 94.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.6% return, outperforming this stock by 249.8%

Performance

  • $159.01
    $166.68
    $165.70
    downward going graph

    4.04%

    Downside

    Day's Volatility :4.6%

    Upside

    0.58%

    downward going graph
  • $141.98
    $218.88
    $165.70
    downward going graph

    14.32%

    Downside

    52 Weeks Volatility :35.13%

    Upside

    24.3%

    downward going graph

Returns

PeriodAlnylam Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
13.1%
0.9%
0.0%
6 Months
-13.26%
8.7%
0.0%
1 Year
-16.76%
10.9%
0.0%
3 Years
-4.19%
17.4%
-23.0%

Highlights

Market Capitalization
20.4B
Book Value
- $1.73
Earnings Per Share (EPS)
-2.64
PEG Ratio
-0.49
Wall Street Target Price
219.48
Profit Margin
-16.58%
Operating Margin TTM
-8.79%
Return On Assets TTM
-3.05%
Return On Equity TTM
-1500.66%
Revenue TTM
2.0B
Revenue Per Share TTM
15.97
Quarterly Revenue Growth YOY
54.800000000000004%
Gross Profit TTM
868.6M
EBITDA
-122.3M
Diluted Eps TTM
-2.64
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.47
EPS Estimate Next Year
-1.86
EPS Estimate Current Quarter
-1.18
EPS Estimate Next Quarter
-1.04

Analyst Recommendation

Buy
    70%Buy
    29%Hold
    0
    0%Sell
Based on 34 Wall street analysts offering stock ratings for Alnylam Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 34 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
24
24
25
Hold
10
10
8
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 32.46%

Current $165.70
Target $219.48

Company Financials

FY18Y/Y Change
Revenue
74.9M
↓ 16.69%
Net Income
-761.5M
↑ 55.13%
Net Profit Margin
-1.0K%
↓ 470.63%
FY19Y/Y Change
Revenue
219.8M
↑ 193.36%
Net Income
-886.1M
↑ 16.37%
Net Profit Margin
-403.24%
↑ 613.34%
FY20Y/Y Change
Revenue
492.9M
↑ 124.28%
Net Income
-858.3M
↓ 3.14%
Net Profit Margin
-174.15%
↑ 229.09%
FY21Y/Y Change
Revenue
844.3M
↑ 71.31%
Net Income
-852.8M
↓ 0.64%
Net Profit Margin
-101.01%
↑ 73.14%
FY22Y/Y Change
Revenue
1.0B
↑ 22.88%
Net Income
-1.1B
↑ 32.64%
Net Profit Margin
-109.04%
↓ 8.03%
FY23Y/Y Change
Revenue
1.8B
↑ 76.23%
Net Income
-440.2M
↓ 61.08%
Net Profit Margin
-24.08%
↑ 84.96%
Q4 FY22Q/Q Change
Revenue
335.0M
↑ 26.76%
Net Income
-207.5M
↓ 48.88%
Net Profit Margin
-61.93%
↑ 91.65%
Q1 FY23Q/Q Change
Revenue
319.3M
↓ 4.7%
Net Income
-174.1M
↓ 16.09%
Net Profit Margin
-54.53%
↑ 7.4%
Q2 FY23Q/Q Change
Revenue
318.8M
↓ 0.17%
Net Income
-276.0M
↑ 58.54%
Net Profit Margin
-86.59%
↓ 32.06%
Q3 FY23Q/Q Change
Revenue
750.5M
↑ 135.46%
Net Income
147.8M
↓ 153.53%
Net Profit Margin
19.69%
↑ 106.28%
Q4 FY23Q/Q Change
Revenue
439.7M
↓ 41.41%
Net Income
-137.9M
↓ 193.31%
Net Profit Margin
-31.35%
↓ 51.04%
Q1 FY24Q/Q Change
Revenue
494.3M
↑ 12.42%
Net Income
-65.9M
↓ 52.18%
Net Profit Margin
-13.34%
↑ 18.01%
FY18Y/Y Change
Total Assets
1.6B
↓ 21.05%
Total Liabilities
272.8M
↑ 19.51%
FY19Y/Y Change
Total Assets
2.4B
↑ 52.09%
Total Liabilities
956.4M
↑ 250.55%
FY20Y/Y Change
Total Assets
3.4B
↑ 42.25%
Total Liabilities
2.4B
↑ 149.97%
FY21Y/Y Change
Total Assets
3.6B
↑ 6.93%
Total Liabilities
3.1B
↑ 27.78%
FY22Y/Y Change
Total Assets
3.5B
↓ 2.66%
Total Liabilities
3.7B
↑ 21.26%
FY23Y/Y Change
Total Assets
3.8B
↑ 7.99%
Total Liabilities
4.1B
↑ 9.34%
Q4 FY22Q/Q Change
Total Assets
3.5B
↑ 0.31%
Total Liabilities
3.7B
↑ 2.82%
Q1 FY23Q/Q Change
Total Assets
3.4B
↓ 4.35%
Total Liabilities
3.7B
↓ 1.44%
Q2 FY23Q/Q Change
Total Assets
3.4B
↑ 0.31%
Total Liabilities
3.8B
↑ 4.36%
Q3 FY23Q/Q Change
Total Assets
3.8B
↑ 12.83%
Total Liabilities
4.0B
↑ 5.1%
Q4 FY23Q/Q Change
Total Assets
3.8B
↓ 0.24%
Total Liabilities
4.1B
↑ 1.14%
Q1 FY24Q/Q Change
Total Assets
3.8B
↓ 0.14%
Total Liabilities
4.0B
↓ 0.17%
FY18Y/Y Change
Operating Cash Flow
-562.6M
↑ 46.98%
Investing Cash Flow
272.9M
↓ 194.0%
Financing Cash Flow
65.5M
↓ 94.18%
FY19Y/Y Change
Operating Cash Flow
-278.4M
↓ 50.51%
Investing Cash Flow
-417.7M
↓ 253.03%
Financing Cash Flow
823.2M
↑ 1157.35%
FY20Y/Y Change
Operating Cash Flow
-615.0M
↑ 120.87%
Investing Cash Flow
-435.5M
↑ 4.27%
Financing Cash Flow
995.0M
↑ 20.87%
FY21Y/Y Change
Operating Cash Flow
-641.7M
↑ 4.35%
Investing Cash Flow
-273.3M
↓ 37.25%
Financing Cash Flow
1.2B
↑ 25.34%
FY22Y/Y Change
Operating Cash Flow
-541.3M
↓ 15.65%
Investing Cash Flow
169.4M
↓ 161.97%
Financing Cash Flow
425.8M
↓ 65.86%
Q4 FY22Q/Q Change
Operating Cash Flow
-132.0M
↑ 14.48%
Investing Cash Flow
-139.9M
↓ 144.57%
Financing Cash Flow
63.4M
↓ 78.64%
Q1 FY23Q/Q Change
Operating Cash Flow
-166.5M
↑ 26.14%
Investing Cash Flow
-76.2M
↓ 45.52%
Financing Cash Flow
46.4M
↓ 26.9%
Q2 FY23Q/Q Change
Operating Cash Flow
-59.0M
↓ 64.57%
Investing Cash Flow
-8.7M
↓ 88.57%
Financing Cash Flow
53.4M
↑ 15.15%
Q3 FY23Q/Q Change
Operating Cash Flow
359.4M
↓ 709.32%
Investing Cash Flow
-10.8M
↑ 23.54%
Financing Cash Flow
33.1M
↓ 37.94%

Technicals Summary

Sell

Neutral

Buy

Alnylam Pharmaceuticals, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
9.81%
-13.26%
-16.76%
-4.19%
130.78%
Moderna, Inc.
Moderna, Inc.
-18.32%
40.58%
10.72%
-39.74%
850.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
7.05%
24.38%
35.05%
97.21%
236.95%
Novo Nordisk A/s
Novo Nordisk A/s
5.92%
38.21%
77.43%
245.57%
453.56%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.73%
15.66%
34.62%
148.17%
158.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-3.47
-15.01
-0.03
NA
-1.73
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.7
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.93
30.93
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.78
49.78
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.61
30.61
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$20.4B
130.78%
NA
-16.58%
Moderna, Inc.
Moderna, Inc.
Buy
$51.5B
850.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$115.3B
236.95%
30.93
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$644.0B
453.56%
49.78
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.7B
158.93%
30.61
39.46%

Institutional Holdings

  • Capital World Investors

    10.11%
  • Vanguard Group Inc

    9.48%
  • FMR Inc

    7.88%
  • BlackRock Inc

    7.13%
  • Wellington Management Company LLP

    5.70%
  • Baillie Gifford & Co Limited.

    5.24%

Corporate Announcements

  • Alnylam Pharmaceuticals, Inc. Earnings

    Alnylam Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

Organization
Alnylam Pharmaceuticals, Inc.
Employees
2100
CEO
Dr. Yvonne L. Greenstreet M.B.A., MBChB
Industry
Health Technology

FAQs